Upload
marla
View
40
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Discussion Gastric Cancer LBA 4002, abstracts 4003, 4004. Florian Lordick, MD Germany. Gastric Cancer. Lung (1.4 million deaths) Stomach (740 000 deaths) Liver (700 000 deaths) Colorectal (610 000 deaths) Breast (460 000 deaths) http://www.who.int factsheet N°297 February 2011. - PowerPoint PPT Presentation
Citation preview
Discussion Gastric CancerLBA 4002, abstracts 4003, 4004
Florian Lordick, MDGermany
Gastric Cancer
• Lung (1.4 million deaths)• Stomach (740 000 deaths)• Liver (700 000 deaths)• Colorectal (610 000 deaths)• Breast (460 000 deaths)
http://www.who.int factsheet N°297 February 2011
Yung-Jue Bang et al. LBA 4002CLASSIC – Adjuvant Chemotherapy
• Asia: Korea, China, Taiwan• Surgical technique: D2 resection
Surgically (D2) resected Stage II, IIIA, or IIIB* GC, 6 weeks prior to randomization
No prior chemotherapy or
radiotherapy
Capecitabine: 1,000 mg/m2 bid, d1–14, q3wOxaliplatin: 130 mg/m2, d1, q3w
RANDO MIZATION
8 cycles of XELOX (6 months)
Observation: No adjuvant therapy
N = 1035
n = 520
n = 515
• Primary endpoint: 3-year DFS‡
• Secondary endpoints: overall survival and safety profile
CLASSIC – Primary Endpoint Met(3-year DFS at Interim Analysis)
ITT populationMedian follow-up 34.4 months (range 16–51)
1.0
0.0
0.2
0.4
0.6
0.8
3-year DFS
74%
60%
HR = 0.56 (95% CI 0.44–0.72)P < .0001
Time (months)
Observation, n = 515
XELOX, n = 520
520 410 333 246 166 74 30 10443515 352 286 209 147 58 22 6414
XELOXObservation
No. left
0 6 12 18 24 30 36 42 48
CLASSIC – Overall Survival
ITT populationMedian follow-up 34.4 months (range 16–51)
1.0
0.0
0.2
0.4
0.6
0.8
Overall survival
0 6 12 18 24 30 36 42 48
HR = 0.74 (95% CI 0.53–1.03)P = .0775
Observation n = 515
XELOX, n = 520
Time (months)
520 451 395 304 216 120 35 16468515 441 378 286 203 112 34 12458
XELOXObservation
No. left
CLASSIC – Discussion
Is the positive result of CLASSIC surprising?
No, it’s not!
CLASSIC – Discussion
ATCS-GC (Japan): S-1 vs. surgery alone
Sakuramoto S et al. N Engl J Med 2007;357:1810-1820
Relapse-free survival Overall survival
HR = 0.62 (95% CI, 0.50 to 0.77)P<0.001
HR = 0.68 (95% CI, 0.52 to 0.87)P = 0.003
CLASSIC – Discussion
GASTRIC Group Meta-analysis
The Gastric Group. JAMA 2010; 303: 1729-1737
6% difference at 5 yearsHR = 0.82; p < 0.001
CLASSIC – Discussion
Are the results of CLASSIC transferable to the Western World?
There are some caveats!
CLASSIC – Discussion
• Median age (Classic): 56 years
Age-specific incidence rate for gastric cancer in German males
Robert-Koch-Institute 2010
CLASSIC – Discussion
• Tumor location (Classic): mid & distal 78%
Devesa et al. Cancer 1998; 83: 2049-2053
Change of gastric cancerepidemiology in theWestern World
CLASSIC – Discussion
• D2 resection (Classic):median 42 lymph nodes examined (range 9-127)
US INT 0116 (SWOG 9008)Macdonald et al. 2001
D2-Resection 10%
D1-Resection 36%
D0-Resection 54%
UK MAGICCunningham et al. 2006
D2-Resection 41%
D1-Resection 19%
Other Resections 40%
Gastric Cancer – Discussion
Does the surgical approach determinethe optimal adjuvant treatment strategy?
Asia: Radical resection (D2)Adjuvant chemotherapy
Sub-radical resection (≤ D 1)Adjuvant chemoradiation
Charles S Fuchs et al. # 4003 CALGB 80101 – Adjuvant Chemoradiation
• North America: Intergroup study
R
A
N
D
O
M
I
Z
E
5-FU/LVx 1
5-FU/LVx 2
5-FU IVCI
RT
ECFx 1
ECFx 2
5-FU IVCI
RT
N = 540Stratification by T stage, N stage, < or ≥ 7 examined lymph nodesPrimary endpoint: improvement in overall survival
CALGB 80101 – Adverse Events ≥ 3
5FU/LV ECF
Nausea 17% 15%
Diarrhea 15% 7%
Mucositis 15% 7%
Dehydration 9% 4%
Anorexia 16% 13%
Fatigue 11% 13%
Neutropenia 52% 48%
Grade ≥ 4 Neutropenia 33% 19%
Death 3% (8) 0% (1)
CALGB 80101 – Disease-free Survival
0 1 2 3 4 5 6 7
Years from Study Entry
0.0
0.2
0.4
0.6
0.8
1.0
Pro
po
rtio
n S
urv
ivin
g D
ise
as
e-F
ree
ECF5-FU
Disease_Free Survival by Arm
P, log rank = 0.99
CALGB 80101 – Overall Survival
0 1 2 3 4 5 6 7
Years from Study Entry
0.0
0.2
0.4
0.6
0.8
1.0
Pro
po
rtio
n S
urv
ivin
g
ECF5-FU
Overall Survival by Arm
P, log rank = 0.80
CALGB 80101 – Discussion
Is the result of CALGB 80101 surprising?
No, it’s not surprising!
CALGB 80101 – Discussion
Cascinu et al. JNCI 2007; 99: 601-607
GISCAD adjuvant PELF vs FU
CALGB 80101 – Discussion
GASTRIC Group Meta-analysis
The Gastric Group. JAMA 2010; 303: 1729-1737
Hazard Ratio 95% CI
Monotherapy 0.56 0.42 - 0.75
Combination withanthracycline 0.85 0.75 – 0.97
Other combinations 0.86 0.77 – 0.88
Therapy of Gastric Cancer in the U.S.
CALGB 80101Fuchs et al. 2011
INT 0116Macdonald et al. 2001
5-FU/LV ECF 5-FU/RT Control
Median OS
(mos)37 38 36 27
CALGB 80101- Discussion
What could we make better?
Radiation quality assurance
CALGB 80101 (Fuchs et al. 2011)15% of the treatment plans were foundto contain major deviations
INT 0116 (Macdonald et al. 2001)6.5% major deviations
CALGB 80101- Discussion
Surgical quality assurance
CALGB 80101 (Fuchs et al. 2011)D2 LN dissection not mandated33% pts had <15 lymph nodes examined!
What could we make better?
• Role of D2 lymph node dissection
Long-term follow-upof the Dutch D1/D2 trial
Songun et al. Lancet Oncol 2010; 11: 439-449
ESMO Practice GuidelinesOkines et al. Ann Oncol 2010, 21 (suppl5); v50-v54
NCCN Guidelines v 2.2011www.nccn.com
CALGB 80101- Discussion
CALGB 80101- Discussion
NCCN v2.2011 guidelines:Gastric resection should include the regional lymphatics: perigastric lymph nodes (D1) and those along the named vessels of the celiac axis (D2) with a goal of examining at least 15 or greater lymph nodes.
Surgical experience & hospital volume matter!
Summary Adjuvant Gastric Cancer
EuropePerioperative CTx(Epirubicin)-Platin-5FU
AsiaAdjuvant CTxS-1 or Capox
N America
Adjuvant R-CTx45 Gy + 5FU/LV
Advanced Gastric Cancer
Wagner et al. J Clin Oncol 2006; 24: 2903-9
• 1st line chemotherapy prolongs survival• 1st line chemotherapy improves symptom control
Established standard 1st line:Platin-fluoropyrimidine-combinations
Park et al. # 4004Is there a role for second-line chemotherapy?
2nd line Chemotherapy (SLC)Park et al. #4004
Refused RCT, but prefer SLC
Willing to participate RCT
Screening & consent for RCT
Refused RCT, but prefer BSC
SLC SLC BSC BSC
2:1 randomization
RCT
RCT + PPT
Docetaxelor irinotecan
ClinicalTrials.gov,NCT00821990
RCT: randomized controlled trialPPT: patient-preference trial
N = 202
Survival (Park et al. #4004)
0 6 12 180.0
0.2
0.4
0.6
0.8
1.0
Su
rviv
alP
rob
abil
ity
Months
SLC + BSC 5.1 mo 4.0-6.2
BSC alone 3.8 mo 3.0-4.6
Median 95% CI
Log-rankP=0.009
Median f/u (95% CI): 17 mo (16-18 mo)
Critizism (Park et al. #4004)
• Data on quality of life
• Data on symptom improvement / control
I missed…
Post progression chemotherapy
Thuss-Patience P. Eur J Cancer; 2011; accepted for publication
Irinotecan(n = 21)
BSC(n = 19)
Symptomimprovement
44 % 5 %
Survival(median)
4 mon 2.4 mon P = 0.0027HR = 0.48
95%CI [0,25-0,92]
German AIO Study
Park et al. #4004 Conclusion
2nd line chemotherapy has aproven benefit in advanced gastric cancer
and should be offered to patients
with an acceptable Karnofksy PSand
motivation to receive further chemotherapy
Thank you for your kind attention…
… and have a safe trip home!